scout
|Videos|August 17, 2017

Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALL

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME